StockMacro
Menu

PMGC

$1.14 -93% in 6 monthsMarket cap $1.3M

ELAB on XNAS, Health Care, PMGC Holdings Inc., job postings

Measures activity, not value. Not investment advice.

Shares down more than 99% in a year while cash of $114M sits on the balance sheet.

  • BadNet loss of $13.3M over 12 months on revenue of $4.8M

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

PMGC Holdings Inc IS advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.

Industry
Pharmaceutical preparations (Health Care)
Employees
34
Website
pmgcholdings.com
Listed
Nasdaq, US
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $2.5M, net loss $2.4M.
Quarter to 30 Sep 2022: revenue –, net income -$499.1MQuarter to 31 Dec 2022: revenue –, net income $1.1BQuarter to 31 Mar 2023: revenue $143K, net income -$1.1MQuarter to 31 Mar 2023: revenue $143K, net income -$1.1MQuarter to 30 Jun 2023: revenue $317K, net income -$1.3MQuarter to 30 Jun 2023: revenue $317K, net income -$1.3MQuarter to 30 Sep 2023: revenue –, net income -$783.0MQuarter to 31 Dec 2023: revenue –, net income $3.1BQuarter to 31 Mar 2024: revenue $615K, net income -$1.4MQuarter to 31 Mar 2024: revenue $615K, net income -$1.4MQuarter to 30 Jun 2024: revenue $606K, net income -$1.4MQuarter to 30 Jun 2024: revenue $606K, net income -$1.4MQuarter to 30 Sep 2024: revenue $527K, net income -$1.5MQuarter to 30 Sep 2024: revenue $527K, net income -$1.5MQuarter to 31 Dec 2024: revenue –, net income -$1.9MQuarter to 31 Mar 2025: revenue –, net income -$1.6MQuarter to 30 Jun 2025: revenue –, net income -$562KQuarter to 30 Sep 2025: revenue $286K, net income -$2.6MQuarter to 30 Sep 2025: revenue $286K, net income -$2.6MQuarter to 31 Dec 2025: revenue $304K, net income -$3.0MQuarter to 31 Dec 2025: revenue $304K, net income -$3.0MQuarter to 31 Mar 2026: revenue $682K, net income -$5.0MQuarter to 31 Mar 2026: revenue $682K, net income -$5.0MQuarter to 30 Jun 2026: revenue $1.3M, net income -$2.9MQuarter to 30 Jun 2026: revenue $1.3M, net income -$2.9MQuarter to 30 Sep 2026: revenue $2.5M, net income -$2.4MQuarter to 30 Sep 2026: revenue $2.5M, net income -$2.4M
30 Sep 2022RevenueNet incomeNet losstallest bar $3.1B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$2.5M-$2.4M
30 Jun 2026$1.3M-$2.9M
31 Mar 2026$682K-$5.0M
31 Dec 2025$304K-$3.0M
30 Sep 2025$286K-$2.6M
30 Jun 2025–-$562K
31 Mar 2025–-$1.6M
31 Dec 2024–-$1.9M
30 Sep 2024$527K-$1.5M
30 Jun 2024$606K-$1.4M
31 Mar 2024$615K-$1.4M
31 Dec 2023–$3.1B
30 Sep 2023–-$783.0M
30 Jun 2023$317K-$1.3M
31 Mar 2023$143K-$1.1M
31 Dec 2022–$1.1B
30 Sep 2022–-$499.1M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $4.8M –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$13.3M -$6.7M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 27.5% – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -276% – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -129% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $114.0M $8.5M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $7.3M $3.2M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$106.7M (net cash) -$5.3M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.60 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $10.36
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 0.28 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.11 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
PMGCELAB (this company) $1.3Mloss0.28–-276%
Artelo BiosciencesARTL $1.3Mloss–––
Aptevo TherapeuticsAPVO $1.4Mloss–––
Jupiter NeurosciencesJUNS $1.6Mloss–––
Kala BIOKALA $1.7Mloss–––
Propanc BiopharmaPPCB $1.7Mloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

–

No data for this company

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

1.7%

20K shares held by 13F filers (30 Sep 2026) of 1.2M outstanding (11 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

1.6%

19K shares sold short (30 Oct 2026) of 1.2M outstanding (11 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

2.6

19K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+0.7%

19K shares sold short in the report before, 19K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

17%

17% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 48%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

13

13 articles in the last 7 days; its usual week has 0.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

13 articles in the last 7 days; its usual week has 0.5: fewer than one, so there is nothing to compare with.

Price $1.14 on 20 Nov 2026, -100% over 12 months (12-month range $1.14 to $1,291.20)

  • Sharp change
  • 8-K and other filings
Revenue per quarter. Revenue $2.5M in the latest quarter, +785% on a year earlier.
Capital spending per quarter. Capital spending $361K in the latest quarter.
Institutional holders (13F filers). 5 13F filers reported holding it in the latest 13F quarter, +25% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: insider net buying (open market), h-1b/e-3 applications certified, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
16 Jun 2026Sharp changeShort interest spike: short interest spike, 600K vs usual 88K (2026-05-29); 8.6x the same period a year earlier
13 May 20268-K and other filingsCompleted an acquisition or asset sale
14 Apr 2026Sharp changeShort interest spike: short interest spike, 1.6M vs usual 84K (2026-03-31); 21.0x the same period a year earlier
6 Feb 20268-K and other filingsCompleted an acquisition or asset sale
26 Nov 20258-K and other filingsRegistered new securities for sale (S-1)
26 Nov 20258-K and other filingsRegistered new securities for sale (S-1)
30 Oct 20258-K and other filingsCompleted an acquisition or asset sale
15 Oct 20258-K and other filingsRegistered new securities for sale (S-1)
15 Oct 20258-K and other filingsRegistered new securities for sale (S-1)
20 Sep 20258-K and other filingsRegistered new securities for sale (S-1)
22 Jul 20258-K and other filingsCompleted an acquisition or asset sale
11 Jul 20258-K and other filingsCompleted an acquisition or asset sale
7 Apr 20258-K and other filingsDelisting notice or listing transfer
7 Apr 20258-K and other filingsRegistered new securities for sale (S-1)
3 Mar 20258-K and other filingsA major agreement ended
12 Feb 20258-K and other filingsRegistered new securities for sale (S-1)
16 Jan 20258-K and other filingsCompleted an acquisition or asset sale
31 Dec 20248-K and other filingsDirector or officer change
31 Dec 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
23 Dec 20248-K and other filingsChanged its auditor
19 Sep 20248-K and other filingsRegistered new securities for sale (S-1)
16 Sep 20248-K and other filingsRegistered new securities for sale (S-1)
6 Sep 20248-K and other filingsRegistered new securities for sale (S-1)
6 Sep 20248-K and other filingsDelisting notice or listing transfer
5 Aug 20248-K and other filingsDirector or officer change
26 Jun 20248-K and other filingsDirector or officer change
26 Jun 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
24 May 20248-K and other filingsDelisting notice or listing transfer
7 Mar 20248-K and other filingsDirector or officer change
7 Mar 20248-K and other filingsDelisting notice or listing transfer
7 Mar 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
9 Nov 20238-K and other filingsRegistered new securities for sale (S-1)
3 Nov 20238-K and other filingsRegistered new securities for sale (S-1)
28 Sep 20238-K and other filingsRegistered new securities for sale (S-1)
22 Sep 20238-K and other filingsPrivate placement of securities (Form D)
27 Apr 20238-K and other filingsPrivate placement of securities (Form D)
16 Mar 20238-K and other filingsPrivate placement of securities (Form D)
28 Jul 20228-K and other filingsPrivate placement of securities (Form D)
Revenue per quarter
Quarter ended 31 Mar 2023: $143K; public on 16 May 2024
Quarter ended 30 Jun 2023: $317K; public on 15 Aug 2024
Quarter ended 31 Mar 2024: $615K, +330% on a year earlier; public on 16 May 2024
Quarter ended 30 Jun 2024: $606K, +91% on a year earlier; public on 15 Aug 2024
Quarter ended 30 Sep 2024: $527K; public on 15 Nov 2024
Quarter ended 30 Sep 2025: $286K, -46% on a year earlier; public on 15 Nov 2025
Quarter ended 31 Dec 2025: $304K; public on 31 Mar 2026
Quarter ended 31 Mar 2026: $682K; public on 16 May 2026
Quarter ended 30 Jun 2026: $1.3M; public on 15 Aug 2026
Quarter ended 30 Sep 2026: $2.5M, +785% on a year earlier; public on 14 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2023: $11K; public on 16 May 2024
Quarter ended 30 Jun 2023: $0; public on 15 Aug 2024
Quarter ended 30 Sep 2023: $0; public on 15 Nov 2024
Quarter ended 31 Dec 2023: $0; public on 29 Mar 2025
Quarter ended 31 Mar 2024: $9K, -18% on a year earlier; public on 16 May 2024
Quarter ended 30 Jun 2024: $0; public on 15 Aug 2024
Quarter ended 30 Sep 2024: $0; public on 15 Nov 2024
Quarter ended 31 Dec 2024: $0; public on 29 Mar 2025
Quarter ended 31 Dec 2025: $347K; public on 31 Mar 2026
Quarter ended 31 Mar 2026: $363K; public on 16 May 2026
Quarter ended 30 Sep 2026: $361K; public on 14 Nov 2026
Institutional holders (13F filers)
31 Dec 2024 report: 4; public on 14 Feb 2025
31 Mar 2025 report: 5; public on 15 May 2025
30 Jun 2025 report: 4; public on 14 Aug 2025
30 Sep 2025 report: 4; public on 14 Nov 2025
31 Dec 2025 report: 3; public on 17 Feb 2026
31 Mar 2026 report: 6; public on 15 May 2026
30 Jun 2026 report: 12; public on 14 Aug 2026
30 Sep 2026 report: 5; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is capital expenditure, fiscal year at $442K (31 Dec 2025), 43× its normal quarter.
  • Short interest spike: had 600K shares sold short in the 29 May 2026 report, 8.6× the same report last year Public on 10 Jun 2026.
  • Revenue per quarter: Revenue $2.5M in the latest quarter, +785% on a year earlier.
  • Capital spending per quarter: Capital spending $361K in the latest quarter.

Latest records

The names and amounts behind the totals, newest first

5 institutions reported shares at the end of Q3 2026, 2% of the shares outstanding; 0 opened a position, 6 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Jane Street Group, LLC10K0.86%$36K-71K-88%
Vanguard Fiduciary Trust Co3,4010.29%$12K-31K-90%
UBS Group AG2,9740.25%$11K+622+26%
Vanguard Capital Management LLC1,6670.14%$6K-15K-90%
Tower Research Capital LLC (TRC)1,4230.12%$5K-1,082-43%
Robinhood Markets, Inc.100.00%$35

Company events

All 76 company events

In 12 months: 15 major agreements, 2 share registrations, 2 completed deals. Results releases and routine reports are left out.

FiledWhat happenedSource
5 Nov 2026Signed a major agreement8-K
2 Nov 2026Signed a major agreement8-K
2 Sep 2026Signed a major agreementSame filing: changed shareholder rights, changed its bylaws or fiscal year8-K
27 Aug 2026Signed a major agreementSame filing: changed shareholder rights, changed its bylaws or fiscal year8-K
9 Jul 2026Signed a major agreement8-K
7 Jul 2026Signed a major agreement8-K
5 Jun 2026Signed a major agreement8-K
13 May 2026Signed a major agreement; Completed an acquisition or asset sale8-K

The 5 newest of 53 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 10 Jun 2026Short interest and volume change

    had 600K shares sold short in the 29 May 2026 report, 8.6× the same report last year.

    Same report last year: 70K; its normal report is 88K.

    See the evidence
    This period
    600K (the 29 May 2026 report)
    Normal report (median of 24 earlier)
    88K
    Typical spread (median absolute deviation)
    52K
    How far from its usual level
    +6.7
    Same report last year
    70K
    History used
    911 days
    2025-05-30: 70K2025-06-13: 221K2025-06-30: 145K2025-07-15: 240K2025-07-31: 107K2025-08-15: 93K2025-08-29: 80K2025-09-15: 18K2025-09-30: 19K2025-10-15: 427K2025-10-31: 89K2025-11-14: 68K2025-11-28: 57K2025-12-15: 39K2025-12-31: 81K2026-01-15: 39K2026-01-30: 31K2026-02-13: 130K2026-02-27: 87K2026-03-13: 33K2026-03-31: 1.6M2026-04-15: 415K2026-04-30: 236K2026-05-15: 385K2026-05-29: 600K
    the 29 May 2026 report24 earlier reportsnormal: 88K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  2. 13 May 2026Filings record

    Completed an acquisition or asset sale

  3. 11 Apr 2026Short interest and volume change

    had 1.6M shares sold short in the 31 Mar 2026 report, 21× the same report last year.

    Same report last year: 78K; its normal report is 84K.

    See the evidence
    This period
    1.6M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    84K
    Typical spread (median absolute deviation)
    33K
    How far from its usual level
    +31.2
    Same report last year
    78K
    History used
    852 days
    2025-03-31: 78K2025-04-15: 123K2025-04-30: 92K2025-05-15: 89K2025-05-30: 70K2025-06-13: 221K2025-06-30: 145K2025-07-15: 240K2025-07-31: 107K2025-08-15: 93K2025-08-29: 80K2025-09-15: 18K2025-09-30: 19K2025-10-15: 427K2025-10-31: 89K2025-11-14: 68K2025-11-28: 57K2025-12-15: 39K2025-12-31: 81K2026-01-15: 39K2026-01-30: 31K2026-02-13: 130K2026-02-27: 87K2026-03-13: 33K2026-03-31: 1.6M
    the 31 Mar 2026 report24 earlier reportsnormal: 84K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  4. 6 Feb 2026Filings record

    Completed an acquisition or asset sale

  5. 26 Nov 2025Filings record

    Registered new securities for sale (S-1) (dated 25 Nov 2025)

  6. 26 Nov 2025Filings record

    Registered new securities for sale (S-1) (dated 25 Nov 2025)

  7. 30 Oct 2025Filings record

    Completed an acquisition or asset sale

  8. 15 Oct 2025Filings record

    Registered new securities for sale (S-1)

  9. 15 Oct 2025Filings record

    Registered new securities for sale (S-1)

  10. 20 Sep 2025Filings record

    Registered new securities for sale (S-1) (dated 19 Sep 2025)

  11. 22 Jul 2025Filings record

    Completed an acquisition or asset sale

  12. 11 Jul 2025Filings record

    Completed an acquisition or asset sale

  13. 7 Apr 2025Filings record

    Delisting notice or listing transfer

  14. 7 Apr 2025Filings record

    Registered new securities for sale (S-1)

  15. 3 Mar 2025Filings record

    A major agreement ended

  16. 12 Feb 2025Filings record

    Registered new securities for sale (S-1)

  17. 16 Jan 2025Filings record

    Completed an acquisition or asset sale

  18. 31 Dec 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  19. 31 Dec 2024Filings record

    Director or officer change

  20. 23 Dec 2024Filings record

    Changed its auditor

  21. 19 Sep 2024Filings record

    Registered new securities for sale (S-1)

  22. 16 Sep 2024Filings record

    Registered new securities for sale (S-1)

  23. 6 Sep 2024Filings record

    Registered new securities for sale (S-1)

  24. 6 Sep 2024Filings record

    Delisting notice or listing transfer

  25. 5 Aug 2024Filings record

    Director or officer change

  26. 26 Jun 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  27. 26 Jun 2024Filings record

    Director or officer change

  28. 24 May 2024Filings record

    Delisting notice or listing transfer

  29. 7 Mar 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  30. 7 Mar 2024Filings record

    Director or officer change

  31. 7 Mar 2024Filings record

    Delisting notice or listing transfer

  32. 9 Nov 2023Filings record

    Registered new securities for sale (S-1)

  33. 3 Nov 2023Filings record

    Registered new securities for sale (S-1)

  34. 28 Sep 2023Filings record

    Registered new securities for sale (S-1)

  35. 22 Sep 2023Filings record

    Private placement of securities (Form D)

  36. 27 Apr 2023Filings record

    Private placement of securities (Form D)

  37. 16 Mar 2023Filings record

    Private placement of securities (Form D)

  38. 28 Jul 2022Filings record

    Private placement of securities (Form D) (dated 27 Jul 2022)

  39. 1 Oct 2021Filings record

    Private placement of securities (Form D)

  40. 1 Oct 2021Filings record

    Private placement of securities (Form D)

Not listed: 78 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001840563
Ticker
ELAB
Domain
pmgcholdings.com
Hq location
CA|NEWPORT BEACH| (1 unverified)
Name
Elevai Labs Inc., PMGC Holdings Inc., Reactive Medical Labs Inc.
  • SEC Form 13F institutional holdings72 data points31 Dec 2024 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)113 records1 Oct 2021 to 13 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)236 data points31 Dec 2021 to 11 Nov 2026
  • FINRA short interest (twice monthly)212 data points30 Nov 2023 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)1506 data points21 Nov 2023 to 20 Nov 2026